PureTech Health plc (NASDAQ: PRTC) Stock Competitors & Peer Comparison
See PRTC's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for PRTC and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PRTC | $17.38 | +2.12% | 4.2B | -3.78 | -$4.60 | N/A |
| VRTX | $514.65 | +2.53% | 130.4B | 27.04 | $19.03 | N/A |
| MRNA | $242.08 | +6.69% | 96.6B | -29.70 | -$8.15 | N/A |
| REGN | $807.48 | +3.25% | 83.1B | 17.70 | $45.63 | +0.46% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $869.72 | +5.34% | 54.4B | 31.36 | $27.73 | N/A |
| RVMDW | $10.41 | +18.43% | 46.7B | -1.18 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $196.55 | +7.91% | 42.1B | -22.28 | -$8.82 | N/A |
| ONC | $384.50 | +3.87% | 41.1B | 67.69 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
PRTC vs VRTX Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, VRTX has a market cap of 130.4B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while VRTX trades at $514.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas VRTX's P/E ratio is 27.04. In terms of profitability, PRTC's ROE is -0.32%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, PRTC is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check VRTX's competition here
Moderna, Inc. (NASDAQ: MRNA)
PRTC vs MRNA Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, MRNA has a market cap of 96.6B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while MRNA trades at $242.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas MRNA's P/E ratio is -29.70. In terms of profitability, PRTC's ROE is -0.32%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, PRTC is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check MRNA's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
PRTC vs REGN Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, REGN has a market cap of 83.1B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while REGN trades at $807.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas REGN's P/E ratio is 17.70. In terms of profitability, PRTC's ROE is -0.32%, compared to REGN's ROE of +0.14%. Regarding short-term risk, PRTC is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
PRTC vs VRNA Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas VRNA's P/E ratio is -102.80. In terms of profitability, PRTC's ROE is -0.32%, compared to VRNA's ROE of -0.61%. Regarding short-term risk, PRTC is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
PRTC vs ARGX Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, ARGX has a market cap of 54.4B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while ARGX trades at $869.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas ARGX's P/E ratio is 31.36. In terms of profitability, PRTC's ROE is -0.32%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, PRTC is less volatile compared to ARGX. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check ARGX's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
PRTC vs RVMDW Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, RVMDW has a market cap of 46.7B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while RVMDW trades at $10.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas RVMDW's P/E ratio is -1.18. In terms of profitability, PRTC's ROE is -0.32%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, PRTC is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check RVMDW's competition here
Seagen Inc. (NASDAQ: SGEN)
PRTC vs SGEN Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas SGEN's P/E ratio is -57.19. In terms of profitability, PRTC's ROE is -0.32%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, PRTC is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check SGEN's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
PRTC vs RVMD Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, RVMD has a market cap of 42.1B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while RVMD trades at $196.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas RVMD's P/E ratio is -22.28. In terms of profitability, PRTC's ROE is -0.32%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, PRTC is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check RVMD's competition here
BeOne Medicines AG (NASDAQ: ONC)
PRTC vs ONC Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, ONC has a market cap of 41.1B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while ONC trades at $384.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas ONC's P/E ratio is 67.69. In terms of profitability, PRTC's ROE is -0.32%, compared to ONC's ROE of +0.14%. Regarding short-term risk, PRTC is less volatile compared to ONC. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
PRTC vs ALNY Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, ALNY has a market cap of 30.9B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while ALNY trades at $230.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas ALNY's P/E ratio is 41.57. In terms of profitability, PRTC's ROE is -0.32%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, PRTC is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
PRTC vs ROIV Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, ROIV has a market cap of 25.2B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while ROIV trades at $34.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas ROIV's P/E ratio is -33.22. In terms of profitability, PRTC's ROE is -0.32%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, PRTC is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check ROIV's competition here
Genmab A/S (NASDAQ: GMAB)
PRTC vs GMAB Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, GMAB has a market cap of 24B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while GMAB trades at $39.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas GMAB's P/E ratio is 29.44. In terms of profitability, PRTC's ROE is -0.32%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, PRTC is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check GMAB's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
PRTC vs UTHR Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, UTHR has a market cap of 23.8B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while UTHR trades at $553.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas UTHR's P/E ratio is 19.82. In terms of profitability, PRTC's ROE is -0.32%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, PRTC is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check UTHR's competition here
Incyte Corporation (NASDAQ: INCY)
PRTC vs INCY Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, INCY has a market cap of 23.6B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while INCY trades at $116.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas INCY's P/E ratio is 15.67. In terms of profitability, PRTC's ROE is -0.32%, compared to INCY's ROE of +0.30%. Regarding short-term risk, PRTC is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
PRTC vs BNTX Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, BNTX has a market cap of 22.9B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while BNTX trades at $91.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas BNTX's P/E ratio is -11.82. In terms of profitability, PRTC's ROE is -0.32%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, PRTC is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check BNTX's competition here
Insmed Incorporated (NASDAQ: INSM)
PRTC vs INSM Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, INSM has a market cap of 20.9B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while INSM trades at $95.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas INSM's P/E ratio is -23.28. In terms of profitability, PRTC's ROE is -0.32%, compared to INSM's ROE of -1.11%. Regarding short-term risk, PRTC is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check INSM's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
PRTC vs BGNE Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas BGNE's P/E ratio is -22.55. In terms of profitability, PRTC's ROE is -0.32%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, PRTC is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
PRTC vs DNA-WT Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, PRTC's ROE is -0.32%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, PRTC is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check DNA-WT's competition here
Exelixis, Inc. (NASDAQ: EXEL)
PRTC vs EXEL Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, EXEL has a market cap of 16.2B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while EXEL trades at $64.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas EXEL's P/E ratio is 18.40. In terms of profitability, PRTC's ROE is -0.32%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, PRTC is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check EXEL's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
PRTC vs ASND Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, ASND has a market cap of 14.6B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while ASND trades at $234.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas ASND's P/E ratio is -96.83. In terms of profitability, PRTC's ROE is -0.32%, compared to ASND's ROE of +1.90%. Regarding short-term risk, PRTC is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check ASND's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
PRTC vs NBIX Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, NBIX has a market cap of 14.4B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while NBIX trades at $142.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas NBIX's P/E ratio is 20.52. In terms of profitability, PRTC's ROE is -0.32%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, PRTC is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check NBIX's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
PRTC vs HALO Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, HALO has a market cap of 14.1B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while HALO trades at $124.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas HALO's P/E ratio is 23.20. In terms of profitability, PRTC's ROE is -0.32%, compared to HALO's ROE of +1.81%. Regarding short-term risk, PRTC is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check HALO's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
PRTC vs JAZZ Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, JAZZ has a market cap of 13.9B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while JAZZ trades at $213.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas JAZZ's P/E ratio is 7.97. In terms of profitability, PRTC's ROE is -0.32%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, PRTC is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
PRTC vs BBIO Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, BBIO has a market cap of 13.2B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while BBIO trades at $67.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas BBIO's P/E ratio is -18.06. In terms of profitability, PRTC's ROE is -0.32%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, PRTC is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check BBIO's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
PRTC vs SMMT Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, SMMT has a market cap of 12.8B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while SMMT trades at $16.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas SMMT's P/E ratio is -14.37. In terms of profitability, PRTC's ROE is -0.32%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, PRTC is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check SMMT's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
PRTC vs KRTX Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas KRTX's P/E ratio is -28.09. In terms of profitability, PRTC's ROE is -0.32%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, PRTC is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check KRTX's competition here
Bio-Techne Corporation (NASDAQ: TECH)
PRTC vs TECH Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, TECH has a market cap of 11.4B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while TECH trades at $72.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas TECH's P/E ratio is 37.41. In terms of profitability, PRTC's ROE is -0.32%, compared to TECH's ROE of +0.09%. Regarding short-term risk, PRTC is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
PRTC vs RNAM Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas RNAM's P/E ratio is -17.39. In terms of profitability, PRTC's ROE is -0.32%, compared to RNAM's ROE of -0.36%. Regarding short-term risk, PRTC is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check RNAM's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
PRTC vs BMRN Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, BMRN has a market cap of 10.9B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while BMRN trades at $56.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas BMRN's P/E ratio is 27.13. In terms of profitability, PRTC's ROE is -0.32%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, PRTC is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check BMRN's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
PRTC vs MDGL Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, MDGL has a market cap of 10.8B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while MDGL trades at $467.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas MDGL's P/E ratio is -36.53. In terms of profitability, PRTC's ROE is -0.32%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, PRTC is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check MDGL's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
PRTC vs PCVX Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, PCVX has a market cap of 10.2B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while PCVX trades at $66.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas PCVX's P/E ratio is -8.68. In terms of profitability, PRTC's ROE is -0.32%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, PRTC is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check PCVX's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
PRTC vs KRYS Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, KRYS has a market cap of 9.6B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while KRYS trades at $325.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas KRYS's P/E ratio is 40.78. In terms of profitability, PRTC's ROE is -0.32%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, PRTC is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check KRYS's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
PRTC vs RXDX Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas RXDX's P/E ratio is -56.47. In terms of profitability, PRTC's ROE is -0.32%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, PRTC is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check RXDX's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
PRTC vs TWST Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, TWST has a market cap of 9.4B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while TWST trades at $142.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas TWST's P/E ratio is -64.28. In terms of profitability, PRTC's ROE is -0.32%, compared to TWST's ROE of -0.30%. Regarding short-term risk, PRTC is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check TWST's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
PRTC vs KYMR Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, KYMR has a market cap of 9.3B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while KYMR trades at $113.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas KYMR's P/E ratio is -35.46. In terms of profitability, PRTC's ROE is -0.32%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, PRTC is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check KYMR's competition here
10x Genomics, Inc. (NASDAQ: TXG)
PRTC vs TXG Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, TXG has a market cap of 9.3B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while TXG trades at $71.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas TXG's P/E ratio is -121.12. In terms of profitability, PRTC's ROE is -0.32%, compared to TXG's ROE of -0.09%. Regarding short-term risk, PRTC is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check TXG's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
PRTC vs IBRX Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, IBRX has a market cap of 9.3B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while IBRX trades at $8.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas IBRX's P/E ratio is -9.04. In terms of profitability, PRTC's ROE is -0.32%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, PRTC is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check IBRX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
PRTC vs NUVL Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas NUVL's P/E ratio is -21.79. In terms of profitability, PRTC's ROE is -0.32%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, PRTC is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
PRTC vs CRNX Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas CRNX's P/E ratio is -16.86. In terms of profitability, PRTC's ROE is -0.32%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, PRTC is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check CRNX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
PRTC vs PTGX Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, PTGX has a market cap of 8.9B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while PTGX trades at $137.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas PTGX's P/E ratio is 133.97. In terms of profitability, PRTC's ROE is -0.32%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, PRTC is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check PTGX's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
PRTC vs CYTK Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, CYTK has a market cap of 8.9B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while CYTK trades at $63.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas CYTK's P/E ratio is -8.86. In terms of profitability, PRTC's ROE is -0.32%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, PRTC is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check CYTK's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
PRTC vs CAI Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, CAI has a market cap of 8.8B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while CAI trades at $31.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas CAI's P/E ratio is 87.41. In terms of profitability, PRTC's ROE is -0.32%, compared to CAI's ROE of +0.19%. Regarding short-term risk, PRTC is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check CAI's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
PRTC vs IMGN Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas IMGN's P/E ratio is -111.55. In terms of profitability, PRTC's ROE is -0.32%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, PRTC is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check IMGN's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
PRTC vs SYRE Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, SYRE has a market cap of 8.4B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while SYRE trades at $91.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas SYRE's P/E ratio is -46.87. In terms of profitability, PRTC's ROE is -0.32%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, PRTC is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check SYRE's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
PRTC vs APGE Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas APGE's P/E ratio is -31.19. In terms of profitability, PRTC's ROE is -0.32%, compared to APGE's ROE of -0.30%. Regarding short-term risk, PRTC is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check APGE's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
PRTC vs BPMC Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas BPMC's P/E ratio is -51.58. In terms of profitability, PRTC's ROE is -0.32%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, PRTC is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check BPMC's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
PRTC vs AXSM Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, AXSM has a market cap of 8.4B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while AXSM trades at $159.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas AXSM's P/E ratio is -41.67. In terms of profitability, PRTC's ROE is -0.32%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, PRTC is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check AXSM's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
PRTC vs TGTX Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, TGTX has a market cap of 8.3B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while TGTX trades at $54.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas TGTX's P/E ratio is 19.76. In terms of profitability, PRTC's ROE is -0.32%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, PRTC is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check TGTX's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
PRTC vs ARWR Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, ARWR has a market cap of 8.3B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while ARWR trades at $58.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas ARWR's P/E ratio is -26.19. In terms of profitability, PRTC's ROE is -0.32%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, PRTC is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check ARWR's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
PRTC vs CERE Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas CERE's P/E ratio is -16.47. In terms of profitability, PRTC's ROE is -0.32%, compared to CERE's ROE of -0.72%. Regarding short-term risk, PRTC is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check CERE's competition here
Abivax S.A. (NASDAQ: ABVX)
PRTC vs ABVX Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, ABVX has a market cap of 8.1B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while ABVX trades at $92.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas ABVX's P/E ratio is -15.17. In terms of profitability, PRTC's ROE is -0.32%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, PRTC is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check ABVX's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
PRTC vs IONS Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, IONS has a market cap of 7.5B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while IONS trades at $45.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas IONS's P/E ratio is -13.88. In terms of profitability, PRTC's ROE is -0.32%, compared to IONS's ROE of -1.11%. Regarding short-term risk, PRTC is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check IONS's competition here
Metsera, Inc. (NASDAQ: MTSR)
PRTC vs MTSR Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas MTSR's P/E ratio is -23.58. In terms of profitability, PRTC's ROE is -0.32%, compared to MTSR's ROE of -0.47%. Regarding short-term risk, PRTC is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check MTSR's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
PRTC vs PRAX Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, PRAX has a market cap of 7.4B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while PRAX trades at $264.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas PRAX's P/E ratio is -20.46. In terms of profitability, PRTC's ROE is -0.32%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, PRTC is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check PRAX's competition here
Merus N.V. (NASDAQ: MRUS)
PRTC vs MRUS Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas MRUS's P/E ratio is -17.05. In terms of profitability, PRTC's ROE is -0.32%, compared to MRUS's ROE of -0.31%. Regarding short-term risk, PRTC is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
PRTC vs ACLX Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas ACLX's P/E ratio is -28.27. In terms of profitability, PRTC's ROE is -0.32%, compared to ACLX's ROE of -0.40%. Regarding short-term risk, PRTC is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check ACLX's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
PRTC vs IOVA Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, IOVA has a market cap of 6.7B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while IOVA trades at $14.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas IOVA's P/E ratio is -20.36. In terms of profitability, PRTC's ROE is -0.32%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, PRTC is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check IOVA's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
PRTC vs RETA Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas RETA's P/E ratio is -66.29. In terms of profitability, PRTC's ROE is -0.32%, compared to RETA's ROE of +0.47%. Regarding short-term risk, PRTC is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check RETA's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
PRTC vs CNTA Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas CNTA's P/E ratio is -22.63. In terms of profitability, PRTC's ROE is -0.32%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, PRTC is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check CNTA's competition here
Belite Bio, Inc (NASDAQ: BLTE)
PRTC vs BLTE Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, BLTE has a market cap of 6.2B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while BLTE trades at $154.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas BLTE's P/E ratio is -82.59. In terms of profitability, PRTC's ROE is -0.32%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, PRTC is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check BLTE's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
PRTC vs RYTM Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, RYTM has a market cap of 6.2B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while RYTM trades at $90.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas RYTM's P/E ratio is -29.00. In terms of profitability, PRTC's ROE is -0.32%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, PRTC is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check RYTM's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
PRTC vs TERN Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, TERN has a market cap of 6.1B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas TERN's P/E ratio is -51.41. In terms of profitability, PRTC's ROE is -0.32%, compared to TERN's ROE of -0.14%. Regarding short-term risk, PRTC is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check TERN's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
PRTC vs LGND Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, LGND has a market cap of 6.1B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while LGND trades at $306.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas LGND's P/E ratio is 33.63. In terms of profitability, PRTC's ROE is -0.32%, compared to LGND's ROE of +0.20%. Regarding short-term risk, PRTC is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check LGND's competition here
Immunovant, Inc. (NASDAQ: IMVT)
PRTC vs IMVT Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, IMVT has a market cap of 5.9B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while IMVT trades at $28.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas IMVT's P/E ratio is -10.14. In terms of profitability, PRTC's ROE is -0.32%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, PRTC is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check IMVT's competition here
Kodiak Sciences Inc. (NASDAQ: KOD)
PRTC vs KOD Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, KOD has a market cap of 5.8B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while KOD trades at $92.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas KOD's P/E ratio is -22.29. In terms of profitability, PRTC's ROE is -0.32%, compared to KOD's ROE of -2.73%. Regarding short-term risk, PRTC is less volatile compared to KOD. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check KOD's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
PRTC vs CDTX Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas CDTX's P/E ratio is -19.77. In terms of profitability, PRTC's ROE is -0.32%, compared to CDTX's ROE of -0.24%. Regarding short-term risk, PRTC is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check CDTX's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
PRTC vs MIRM Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, MIRM has a market cap of 5.5B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while MIRM trades at $85.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas MIRM's P/E ratio is -5.85. In terms of profitability, PRTC's ROE is -0.32%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, PRTC is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check MIRM's competition here
Abcam plc (NASDAQ: ABCM)
PRTC vs ABCM Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, PRTC's ROE is -0.32%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, PRTC is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
PRTC vs ISEE Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas ISEE's P/E ratio is -22.44. In terms of profitability, PRTC's ROE is -0.32%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, PRTC is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check ISEE's competition here
CG Oncology Inc. (NASDAQ: CGON)
PRTC vs CGON Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, CGON has a market cap of 5.5B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while CGON trades at $61.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas CGON's P/E ratio is -23.02. In terms of profitability, PRTC's ROE is -0.32%, compared to CGON's ROE of -0.25%. Regarding short-term risk, PRTC is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check CGON's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
PRTC vs COGT Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, COGT has a market cap of 5.4B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while COGT trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas COGT's P/E ratio is -14.81. In terms of profitability, PRTC's ROE is -0.32%, compared to COGT's ROE of -0.73%. Regarding short-term risk, PRTC is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check COGT's competition here
Veradermics, Incorporated (NYSE: MANE)
PRTC vs MANE Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, MANE has a market cap of 5.3B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while MANE trades at $127.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas MANE's P/E ratio is -40.50. In terms of profitability, PRTC's ROE is -0.32%, compared to MANE's ROE of -0.38%. Regarding short-term risk, PRTC is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check MANE's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
PRTC vs APLS Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas APLS's P/E ratio is 38.35. In terms of profitability, PRTC's ROE is -0.32%, compared to APLS's ROE of +0.40%. Regarding short-term risk, PRTC is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check APLS's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
PRTC vs PTCT Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, PTCT has a market cap of 5.3B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while PTCT trades at $62.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas PTCT's P/E ratio is -27.00. In terms of profitability, PRTC's ROE is -0.32%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, PRTC is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check PTCT's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
PRTC vs ORKA Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, ORKA has a market cap of 5.2B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while ORKA trades at $79.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas ORKA's P/E ratio is -40.77. In terms of profitability, PRTC's ROE is -0.32%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, PRTC is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check ORKA's competition here
Erasca, Inc. (NASDAQ: ERAS)
PRTC vs ERAS Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, ERAS has a market cap of 5.1B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while ERAS trades at $14.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas ERAS's P/E ratio is -15.72. In terms of profitability, PRTC's ROE is -0.32%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, PRTC is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check ERAS's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
PRTC vs SRRK Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, SRRK has a market cap of 5B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while SRRK trades at $41.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas SRRK's P/E ratio is -11.99. In terms of profitability, PRTC's ROE is -0.32%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, PRTC is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check SRRK's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
PRTC vs TVTX Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, TVTX has a market cap of 4.9B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while TVTX trades at $52.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas TVTX's P/E ratio is -116.22. In terms of profitability, PRTC's ROE is -0.32%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, PRTC is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check TVTX's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
PRTC vs CRSP Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, CRSP has a market cap of 4.8B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while CRSP trades at $49.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas CRSP's P/E ratio is -10.48. In terms of profitability, PRTC's ROE is -0.32%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, PRTC is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check CRSP's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
PRTC vs DFTX Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, DFTX has a market cap of 4.7B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while DFTX trades at $35.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas DFTX's P/E ratio is N/A. In terms of profitability, PRTC's ROE is -0.32%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, PRTC is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check DFTX's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
PRTC vs FOLD Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas FOLD's P/E ratio is -161.00. In terms of profitability, PRTC's ROE is -0.32%, compared to FOLD's ROE of -0.02%. Regarding short-term risk, PRTC is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
PRTC vs AKRO Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas AKRO's P/E ratio is -14.57. In terms of profitability, PRTC's ROE is -0.32%, compared to AKRO's ROE of -0.15%. Regarding short-term risk, PRTC is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
PRTC vs ALPN Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas ALPN's P/E ratio is -101.52. In terms of profitability, PRTC's ROE is -0.32%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, PRTC is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check ALPN's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
PRTC vs DNTH Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, DNTH has a market cap of 4.4B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while DNTH trades at $78.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas DNTH's P/E ratio is -18.98. In terms of profitability, PRTC's ROE is -0.32%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, PRTC is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check DNTH's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
PRTC vs EWTX Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, EWTX has a market cap of 4.3B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while EWTX trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas EWTX's P/E ratio is -21.49. In terms of profitability, PRTC's ROE is -0.32%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, PRTC is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check EWTX's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
PRTC vs TNGX Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, TNGX has a market cap of 4.3B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while TNGX trades at $25.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas TNGX's P/E ratio is -30.43. In terms of profitability, PRTC's ROE is -0.32%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, PRTC is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check TNGX's competition here
Opthea Limited (NASDAQ: OPT)
PRTC vs OPT Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas OPT's P/E ratio is -1.52. In terms of profitability, PRTC's ROE is -0.32%, compared to OPT's ROE of +1.18%. Regarding short-term risk, PRTC is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check OPT's competition here
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT)
PRTC vs ARQT Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, ARQT has a market cap of 4.1B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while ARQT trades at $32.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas ARQT's P/E ratio is 156.29. In terms of profitability, PRTC's ROE is -0.32%, compared to ARQT's ROE of +0.15%. Regarding short-term risk, PRTC is less volatile compared to ARQT. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check ARQT's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
PRTC vs MRTX Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas MRTX's P/E ratio is -4.82. In terms of profitability, PRTC's ROE is -0.32%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, PRTC is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check MRTX's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
PRTC vs RLAY Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, RLAY has a market cap of 4B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while RLAY trades at $18.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas RLAY's P/E ratio is -11.75. In terms of profitability, PRTC's ROE is -0.32%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, PRTC is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check RLAY's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
PRTC vs ADPT Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, ADPT has a market cap of 3.9B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while ADPT trades at $24.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas ADPT's P/E ratio is -59.56. In terms of profitability, PRTC's ROE is -0.32%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, PRTC is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check ADPT's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
PRTC vs CPRX Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas CPRX's P/E ratio is 17.49. In terms of profitability, PRTC's ROE is -0.32%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, PRTC is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check CPRX's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
PRTC vs ABCL Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, ABCL has a market cap of 3.8B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while ABCL trades at $11.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas ABCL's P/E ratio is -21.69. In terms of profitability, PRTC's ROE is -0.32%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, PRTC is less volatile compared to ABCL. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check ABCL's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
PRTC vs TLX Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, TLX has a market cap of 3.8B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while TLX trades at $11.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas TLX's P/E ratio is 116.49. In terms of profitability, PRTC's ROE is -0.32%, compared to TLX's ROE of +0.07%. Regarding short-term risk, PRTC is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check TLX's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
PRTC vs RYZB Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas RYZB's P/E ratio is -57.86. In terms of profitability, PRTC's ROE is -0.32%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, PRTC is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
PRTC vs CBAY Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas CBAY's P/E ratio is -32.81. In terms of profitability, PRTC's ROE is -0.32%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, PRTC is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check CBAY's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
PRTC vs AMLX Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, AMLX has a market cap of 3.6B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while AMLX trades at $28.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas AMLX's P/E ratio is -19.18. In terms of profitability, PRTC's ROE is -0.32%, compared to AMLX's ROE of -0.53%. Regarding short-term risk, PRTC is less volatile compared to AMLX. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check AMLX's competition here
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)
PRTC vs SWTX Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas SWTX's P/E ratio is -13.78. In terms of profitability, PRTC's ROE is -0.32%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, PRTC is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check SWTX's competition here
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD)
PRTC vs ACAD Comparison October 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, ACAD has a market cap of 3.5B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while ACAD trades at $20.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas ACAD's P/E ratio is 9.21. In terms of profitability, PRTC's ROE is -0.32%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, PRTC is less volatile compared to ACAD. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check ACAD's competition here